EC grants marketing approval for Chiesi, Protalix’s Fabry disease therapy
2023-05-08
上市批准
Preview
来源: Pharmaceutical Technology
PRX-102 is indicated for the treatment of Fabry disease in adult patients. Credit: Pr Marie-Claire GUBLER, Paris, France / commons.wikimedia.org.
The European Commission (EC) has granted marketing authorisation to Chiesi Global Rare Diseases and Protalix BioTherapeutics’ PRX-102 (pegunigalsidase alfa) in the European Union (EU) to treat Fabry disease in adult patients.
The PEGylated enzyme replacement therapy (ERT), PRX-102 is a plant cell culture-expressed, and chemically modified recombinant version of the α‑Galactosidase‑A enzyme.
Recommended Reports
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - Siremadlin Succinate in Myelofibrosis GlobalData
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - Naratuximab Emtansine in Follicular Lymphoma GlobalData
View allCompanies IntelligenceChiesi LtdProtalix BioTherapeutics IncView all
It was found to have a favourable circulatory half-life of about 80 hours, with targeted enzyme activity in organs that are affected by Fabry disease, in clinical trials.
Chiesi Global Rare Diseases head Giacomo Chiesi said: “People living with Fabry disease often perceive their disease as burdensome and still experience unmet medical needs.
“Our deepest gratitude to all patients and patient advocates who have stood shoulder-to-shoulder with clinical researchers, scientists, and regulators during the clinical development programme, providing the data needed for this approval.”
The authorisation from EC was based on the data obtained from a comprehensive clinical development programme, which was conducted in over 140 patients, who received treatment for up to 7.5 years.
The company stated that PRX-102 has been investigated in ERT-experienced and ERT-naïve patients, including in a head-to-head trial.
It showed non-inferior efficacy to agalsidase beta in controlling the kidney disease, as assessed by the estimated glomerular filtration rate (eGFR) decline.
Protalix BioTherapeutics president and CEO Dror Bashan said: “The European Commission’s approval of PRX-102 is a significant milestone for patients with Fabry disease and their families, providing a new therapeutic option.
“Based on solid results from our robust clinical programmes, PRX-102 has the potential to be widely used for many years to come.”
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。